Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (111-120 of 284) with videos related to

Pageof 29
Sort By:
Clinical Colorectal Cancer|August 8, 2021
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer PatientsRoberto Moretto, Daniele Rossini, Iolanda Capone, et al.
Cancer|July 15, 2017
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancerSatoshi Okazaki, Marta Schirripa, Fotios Loupakis, et al.
Journal of the National Cancer Institute|December 3, 2010
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysisGianluca Masi, Enrico Vasile, Fotios Loupakis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitorsPaolo Manca, Francesca Corti, Rossana Intini, et al.
Scientific Reports|March 7, 2019
The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal of Cancer Research and Clinical Oncology|November 7, 2019
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patientsVincenzo Catalano, Francesca Bergamo, Chiara Cremolini, et al.
Targeted Oncology|July 4, 2013
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecanFotios Loupakis, Chiara Cremolini, Anna Fioravanti, et al.
The Lancet. Oncology|September 5, 2015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, et al.
Tumori|January 7, 2023
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patientsBeatrice Borelli, Stefania Crucitta, Alessandra Boccaccino, et al.
Pageof 29

Showing results (111-120 of 284) with videos related to

Sort By:
Pageof 29
Clinical Colorectal Cancer|August 8, 2021
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer PatientsRoberto Moretto, Daniele Rossini, Iolanda Capone, et al.
Cancer|July 15, 2017
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancerSatoshi Okazaki, Marta Schirripa, Fotios Loupakis, et al.
Journal of the National Cancer Institute|December 3, 2010
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysisGianluca Masi, Enrico Vasile, Fotios Loupakis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitorsPaolo Manca, Francesca Corti, Rossana Intini, et al.
Scientific Reports|March 7, 2019
The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal of Cancer Research and Clinical Oncology|November 7, 2019
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patientsVincenzo Catalano, Francesca Bergamo, Chiara Cremolini, et al.
Targeted Oncology|July 4, 2013
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecanFotios Loupakis, Chiara Cremolini, Anna Fioravanti, et al.
The Lancet. Oncology|September 5, 2015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, et al.
Tumori|January 7, 2023
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patientsBeatrice Borelli, Stefania Crucitta, Alessandra Boccaccino, et al.
Pageof 29